Skip to content
Engage Bio logo

Engage Bio

Engage Bio is a YC Winter 2022 (W22) company. Based in Santa Clara, CA, USA. Team of 5.

  • Synthetic Biology
  • Biotech
  • Healthcare
  • Therapeutics
  • Drug discovery

About Engage Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Engage Bio develops mRNA immunotherapies for solid tumor cancers. Its approach delivers genetic instructions directly into cancer cells, directing them to produce and slowly release therapeutic drugs within the tumor itself. This localized mechanism targets the tumor while leaving surrounding healthy tissue unaffected, replacing the systemic drug delivery that causes broader toxicity in conventional cancer treatments.

From the Y Combinator listing

How Engage Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

mRNA Immunotherapies to Eliminate Cancer

Engage Bio is developing mRNA immunotherapies to defeat cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. Our approach is to provide cancer cells with instructions to make and gradually release our drugs within solid tumors. This local therapy allows us to eliminate tumors while sparing healthy distant tissues.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Santa Clara, CA, USA
Team size
5
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works